Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
159M
-
Number of holders
-
353
-
Total 13F shares, excl. options
-
102M
-
Shares change
-
+3.53M
-
Total reported value, excl. options
-
$3.65B
-
Value change
-
+$110M
-
Put/Call ratio
-
0.78
-
Number of buys
-
187
-
Number of sells
-
-166
-
Price
-
$35.99
Significant Holders of TG THERAPEUTICS, INC. - COMMON STOCK (TGTX) as of Q2 2025
449 filings reported holding TGTX - TG THERAPEUTICS, INC. - COMMON STOCK as of Q2 2025.
TG THERAPEUTICS, INC. - COMMON STOCK (TGTX) has 353 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 102M shares
of 159M outstanding shares and own 63.99% of the company stock.
Largest 10 shareholders include BlackRock, Inc. (21.8M shares), VANGUARD GROUP INC (15.8M shares), STATE STREET CORP (7.62M shares), GEODE CAPITAL MANAGEMENT, LLC (3.49M shares), Clearbridge Investments, LLC (3.05M shares), Soleus Capital Management, L.P. (2.24M shares), Pictet Asset Management Holding SA (1.91M shares), GOLDMAN SACHS GROUP INC (1.57M shares), Hood River Capital Management LLC (1.57M shares), and FMR LLC (1.55M shares).
This table shows the top 353 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.